Key result
Substrate modification targeting low-voltage zones in addition to pulmonary vein isolation shows promise for improving atrial fibrillation ablation outcomes, though large randomized trials are needed.
Why the study?
Does scar homogenization in addition to pulmonary vein isolation improve freedom from atrial fibrillation in patients undergoing AF ablation?
Does scar homogenization in addition to pulmonary vein isolation improve freedom from atrial fibrillation in patients undergoing AF ablation?
While scar homogenization targeting low-voltage zones may improve outcomes in selected patients with persistent AF and atrial fibrosis, current evidence is mixed and routine use requires confirmation from large randomized trials.
Supports PVI as standard for symptomatic paroxysmal AF; leaves open optimal adjunctive strategies pending higher-level evidence.
Atrial fibrillation (AF) ablation has emerged as the preferred rhythm control strategy for symptomatic paroxysmal AF refractory or intolerant to at least one class I or III antiarrhythmic medication. Since the initial observation by Haissaguerre and colleagues, of pulmonary vein triggers initiating atrial fibrillation (AF), pulmonary vein isolation (PVI) has become the cornerstone for paroxysmal AF ablation therapy.
No takes yet. Share an insight, caveat, or question.
Saini et al. (2017) conducted a review in Atrial fibrillation. Scar homogenization (substrate modification) vs. Pulmonary vein isolation (PVI) alone was evaluated. Substrate modification targeting low-voltage zones in addition to pulmonary vein isolation shows promise for improving atrial fibrillation ablation outcomes, though large randomized trials are needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: